CompletedNot Applicable

Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

Canada134 participantsStarted 2016-06

Plain-language summary

The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ transplant patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult kidney, kidney-pancreas, liver transplant recipient, or heart transplant recipient * CMV D+/R- patient or any R+ patient who received antithymocyte globulin induction therapy Exclusion Criteria: * Unable to comply with protocol * Campath (Alemtuzumab) induction * Receiving another investigational compound for CMV treatment or prophylaxis. * Allergy to valganciclovir or ganciclovir * Receiving an investigational compound for prevention or treatment of rejection, or participating in another interventional study

What they're measuring

Symptomatic CMV disease

Timeframe: 1 year

Trial details

NCT IDNCT02784756

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02

View on ClinicalTrials.gov More Cytomegalovirus Viraemia trials